Development of sensors to identify pathogens causing infections
Development and Validation of (Bio)Sensors for the Identification of Pathogens
University of Bologna · NCT06548841
This study is testing new sensors that can quickly and accurately identify germs causing infections to make it easier for people to get diagnosed, whether they have an infection or not.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bologna (other) |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06548841 on ClinicalTrials.gov |
What this trial studies
This study focuses on creating and validating advanced biosensors that can accurately and rapidly identify various pathogens, including bacteria, viruses, and parasites. The goal is to address the limitations of current diagnostic methods, which often require extensive laboratory resources and time. By utilizing nanobiotechnology platforms, the study aims to develop point-of-care tests that can be used in diverse settings, making pathogen detection more accessible and efficient. Participants will include individuals with confirmed infections as well as those without, allowing for a comprehensive evaluation of the biosensor's effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are either positive or negative for specific pathogens like SARS-CoV-2 or P. aeruginosa.
Not a fit: Patients who do not meet the inclusion criteria, such as those under 18 or without any of the specified infections, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to faster and more accurate diagnosis of infectious diseases, improving patient outcomes and treatment efficiency.
How similar studies have performed: Other studies have shown promise in developing point-of-care diagnostic tests, but this specific approach utilizing nanobiotechnology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obtaining informed consent * Age ≥ 18 years * Patients who meet one of the following conditions: SARS-CoV2 positive patients (group 1), SARS-CoV2 negative patients (group 2), P. aeruginosa positive patients (group 3), P. aeruginosa negative patients (group 4), L. infantum positive patients (group 5), L. infantum negative patients (group 6). Exclusion Criteria: * None
Where this trial is running
Bologna
- Department of Medical and Surgical Sciences, University of Bologna — Bologna, Italy (RECRUITING)
Study contacts
- Principal investigator: Tiziana Lazzarotto, PhD — University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Stefania Varani, MD, PhD
- Email: stefania.varani@unibo.it
- Phone: +39 0512143013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Infections, Infection, Bacterial, Infection Viral, Infection, Parasite, SARS CoV 2 Infection, Pseudomonas Aeruginosa Infection, Leishmania Infantum Disease, infections